Influenza A virus H5N1 vaccine - Sinovac Biotech

Drug Profile

Influenza A virus H5N1 vaccine - Sinovac Biotech

Alternative Names: Pandemic influenza H5N1 whole viron inactivated vaccine - Sinovac Biotech; Panflu; Panflu (H5N1)

Latest Information Update: 24 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sinovac Biotech
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 19 Mar 2015 The vaccine is approved in Hong Kong
  • 13 Oct 2009 Registered for prevention of Influenza-A virus H5N1 subtype in Hong Kong (IM)
  • 29 Jun 2009 Registered for Influenza-A virus H5N1 subtype (whole virion) in China (IM) - First Global Approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top